Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.63Last Year’s EPS
-0.6Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -3.95%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant progress in the development and launch of apitegromab for SMA. Financial stability and a clear strategic direction for global market entry are key strengths. However, there are risks related to regulatory processes, market competition, and exploratory studies that could impact future outcomes.Company Guidance
In the first quarter of 2025, Scholar Rock made significant strides in advancing apitegromab for patients with Spinal Muscular Atrophy (SMA). The company highlighted the positive results from the Phase 3 SAPPHIRE trial, which demonstrated a statistically significant and clinically meaningful improvement in motor function measured by the Hammersmith scale. The Biologics License Application (BLA) for apitegromab was granted priority review by the FDA, with a PDUFA date set for September 22, 2025. Scholar Rock is preparing for its US commercial launch, targeting approximately 10,000 SMA patients in the US, with a global reach of about 35,000 who have received SMN-targeted therapies. The company is also exploring additional indications for apitegromab, including other neuromuscular disorders, while advancing its cardiometabolic EMBRAZE study to address muscle mass loss in obesity, with results expected in June. Scholar Rock ended the quarter with $364.4 million in cash and is focused on disciplined capital allocation to support its growth and strategic initiatives into 2027.Positive Phase 3 SAPPHIRE Trial Results
The SAPPHIRE trial showed statistically significant and clinically meaningful improvement in motor function for SMA patients using apitegromab, with a threefold higher chance of improvement versus placebo.
FDA Priority Review and Upcoming Launch
The FDA granted priority review for apitegromab with a PDUFA date set for September 22nd, indicating significant potential impact for SMA treatment.
Global Launch Strategy for Apitegromab
Efforts are underway for a global launch of apitegromab, beginning with the US in Q3 2025, followed by Europe, Asia Pacific, and Latin America.
Strong Financial Position
Scholar Rock ended the quarter with $364.4 million and an additional $100 million available through a debt facility, ensuring financial runway into 2027.
Exploration of New Indications
Scholar Rock is evaluating the use of apitegromab in other neuromuscular disorders and advancing SRK-439 for clinical trials, with an IND filing expected in Q3.
---
SRRK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRRK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $31.40 | $30.54 | -2.74% |
Feb 27, 2025 | $37.02 | $35.96 | -2.86% |
Nov 12, 2024 | $28.15 | $26.66 | -5.29% |
Aug 08, 2024 | $8.25 | $8.17 | -0.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Scholar Rock Holding Corp (SRRK) report earnings?
Scholar Rock Holding Corp (SRRK) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Scholar Rock Holding Corp (SRRK) earnings time?
Scholar Rock Holding Corp (SRRK) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRRK EPS forecast?
SRRK EPS forecast for the fiscal quarter 2025 (Q2) is -0.63.
---